BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BioLife Solutions, Inc. (NASDAQ:BLFS) has been given an average recommendation of “Moderate Buy” by the five analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $32.00.

Several research analysts recently commented on BLFS shares. Zacks Research raised BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 23rd. Northland Securities set a $34.00 price target on shares of BioLife Solutions in a research note on Monday, January 5th. Wall Street Zen downgraded BioLife Solutions from a “buy” rating to a “hold” rating in a report on Sunday, November 30th. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a research report on Monday, December 29th.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $23.09 on Friday. The stock has a market capitalization of $1.11 billion, a PE ratio of -329.81 and a beta of 1.92. The business has a 50 day simple moving average of $24.03 and a 200-day simple moving average of $25.19. BioLife Solutions has a 12 month low of $19.10 and a 12 month high of $29.62.

Insiders Place Their Bets

In other BioLife Solutions news, Director Amy Duross sold 2,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $24.60, for a total transaction of $49,200.00. Following the transaction, the director directly owned 18,687 shares of the company’s stock, valued at approximately $459,700.20. This trade represents a 9.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Troy Wichterman sold 990 shares of the company’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total transaction of $25,334.10. Following the completion of the sale, the chief financial officer directly owned 150,746 shares of the company’s stock, valued at $3,857,590.14. The trade was a 0.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 42,005 shares of company stock valued at $1,080,100. 2.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. purchased a new stake in shares of BioLife Solutions during the 1st quarter worth $283,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in BioLife Solutions by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,422 shares of the medical equipment provider’s stock worth $489,000 after purchasing an additional 914 shares during the last quarter. Jane Street Group LLC purchased a new stake in BioLife Solutions during the first quarter worth $1,091,000. Strs Ohio acquired a new stake in BioLife Solutions in the first quarter valued at $153,000. Finally, AlphaQuest LLC acquired a new stake in BioLife Solutions in the second quarter valued at $149,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.